Arthur W Baker1,2, Eileen K Maziarz1, Sarah S Lewis1,2, Jason E Stout1, Deverick J Anderson1,2, Peter K Smith3, Jacob N Schroder3, Mani A Daneshmand3,4, Barbara D Alexander1,5, Richard J Wallace6, Daniel J Sexton1,2, Cameron R Wolfe1. 1. Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA. 2. Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, USA. 3. Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina, USA. 4. Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USA. 5. Duke University Clinical Microbiology Laboratory, Durham, North Carolina, USA. 6. Mycobacteria/Nocardia Research Laboratory, Department of Microbiology, University of Texas Health Science Center, Tyler, Texas, USA.
Abstract
BACKGROUND: We recently mitigated a clonal outbreak of hospital-acquired Mycobacterium abscessus complex (MABC), which included a large cluster of adult patients who developed invasive infection after exposure to heater-cooler units during cardiac surgery. Recent studies have detailed Mycobacterium chimaera infections acquired during cardiac surgery; however, little is known about the epidemiology and clinical courses of cardiac surgery patients with invasive MABC infection. METHODS: We retrospectively collected clinical data on all patients who underwent cardiac surgery at our hospital and subsequently had positive cultures for MABC from 2013 through 2016. Patients with ventricular assist devices or heart transplants were excluded. We analyzed patient characteristics, antimicrobial therapy, surgical interventions, and clinical outcomes. RESULTS: Ten cardiac surgery patients developed invasive, extrapulmonary infection from M. abscessus subspecies abscessus in an outbreak setting. Median time from presumed inoculation in the operating room to first positive culture was 53 days (interquartile range [IQR], 38-139 days). Disseminated infection was common, and the most frequent culture-positive sites were mediastinum (n = 7) and blood (n = 7). Patients received a median of 24 weeks (IQR, 5-33 weeks) of combination antimicrobial therapy that included multiple intravenous agents. Six patients required antibiotic changes due to adverse events attributed to amikacin, linezolid, or tigecycline. Eight patients underwent surgical management, and 6 patients required multiple sternal debridements. Eight patients died within 2 years of diagnosis, including 4 deaths directly attributable to MABC infection. CONCLUSIONS: Despite aggressive medical and surgical management, invasive MABC infection after cardiac surgery caused substantial morbidity and mortality. New treatment strategies are needed, and compliance with infection prevention guidelines remains critical.
BACKGROUND: We recently mitigated a clonal outbreak of hospital-acquired Mycobacterium abscessus complex (MABC), which included a large cluster of adult patients who developed invasive infection after exposure to heater-cooler units during cardiac surgery. Recent studies have detailed Mycobacterium chimaera infections acquired during cardiac surgery; however, little is known about the epidemiology and clinical courses of cardiac surgery patients with invasive MABC infection. METHODS: We retrospectively collected clinical data on all patients who underwent cardiac surgery at our hospital and subsequently had positive cultures for MABC from 2013 through 2016. Patients with ventricular assist devices or heart transplants were excluded. We analyzed patient characteristics, antimicrobial therapy, surgical interventions, and clinical outcomes. RESULTS: Ten cardiac surgery patients developed invasive, extrapulmonary infection from M. abscessus subspecies abscessus in an outbreak setting. Median time from presumed inoculation in the operating room to first positive culture was 53 days (interquartile range [IQR], 38-139 days). Disseminated infection was common, and the most frequent culture-positive sites were mediastinum (n = 7) and blood (n = 7). Patients received a median of 24 weeks (IQR, 5-33 weeks) of combination antimicrobial therapy that included multiple intravenous agents. Six patients required antibiotic changes due to adverse events attributed to amikacin, linezolid, or tigecycline. Eight patients underwent surgical management, and 6 patients required multiple sternal debridements. Eight patients died within 2 years of diagnosis, including 4 deaths directly attributable to MABC infection. CONCLUSIONS: Despite aggressive medical and surgical management, invasive MABC infection after cardiac surgery caused substantial morbidity and mortality. New treatment strategies are needed, and compliance with infection prevention guidelines remains critical.
Authors: Raphael Hamad; Pierre-Emmanuel Noly; Louis P Perrault; Michel Pellerin; Philippe Demers Journal: Ann Thorac Surg Date: 2017-07 Impact factor: 4.330
Authors: Karla Anacleto de Vasconcelos; Silvana Maria Monte Coelho Frota; Antonio Ruffino-Netto; Afrânio Lineu Kritski Journal: Rev Soc Bras Med Trop Date: 2017 Sep-Oct Impact factor: 1.581
Authors: J E Scriven; A Scobie; N Q Verlander; A Houston; T Collyns; V Cajic; O M Kon; T Mitchell; O Rahama; A Robinson; S Withama; P Wilson; D Maxwell; D Agranoff; E Davies; M Llewelyn; S-S Soo; A Sahota; M A Cooper; M Hunter; J Tomlins; S Tiberi; S Kendall; M Dedicoat; E Alexander; T Fenech; M Zambon; T Lamagni; E G Smith; M Chand Journal: Clin Microbiol Infect Date: 2018-05-25 Impact factor: 8.067
Authors: Meera Chand; Theresa Lamagni; Katharina Kranzer; Jessica Hedge; Ginny Moore; Simon Parks; Samuel Collins; Carlos Del Ojo Elias; Nada Ahmed; Tim Brown; E Grace Smith; Peter Hoffman; Peter Kirwan; Brendan Mason; Alison Smith-Palmer; Philip Veal; Maeve K Lalor; Allan Bennett; James Walker; Alicia Yeap; Antonio Isidro Carrion Martin; Gayle Dolan; Sonia Bhatt; Andrew Skingsley; André Charlett; David Pearce; Katherine Russell; Simon Kendall; Andrew A Klein; Stephen Robins; Silke Schelenz; William Newsholme; Stephanie Thomas; Tim Collyns; Eleri Davies; Jim McMenamin; Lorraine Doherty; Tim E A Peto; Derrick Crook; Maria Zambon; Nick Phin Journal: Clin Infect Dis Date: 2016-12-07 Impact factor: 20.999
Authors: Richard J Wallace; Gary Dukart; Barbara A Brown-Elliott; David E Griffith; Ernesto G Scerpella; Bonnie Marshall Journal: J Antimicrob Chemother Date: 2014-03-14 Impact factor: 5.790
Authors: Shannon A Novosad; Susan E Beekmann; Philip M Polgreen; Kate Mackey; Kevin L Winthrop Journal: Emerg Infect Dis Date: 2016-03 Impact factor: 6.883
Authors: Nicholas Tan; Rahul Sampath; Omar M Abu Saleh; Marysia S Tweet; Dragan Jevremovic; Saba Alniemi; Nancy L Wengenack; Priya Sampathkumar; Andrew D Badley Journal: Open Forum Infect Dis Date: 2016-06-16 Impact factor: 3.835